Pontine Glioma: Pipeline Review H1 2018 - Focus on Therapeutics Development & Assessment, Key Companies Involved and Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Pontine Glioma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
This latest pipeline guide ‘Pontine Glioma - Pipeline Review, H1 2018’, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 12, 8, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively.
Key Topics CoveredIntroduction Pontine Glioma - Overview Pontine Glioma - Therapeutics Development Pontine Glioma - Therapeutics Assessment Pontine Glioma - Companies Involved in Therapeutics Development Pontine Glioma - Drug Profiles Pontine Glioma - Dormant Projects Pontine Glioma - Product Development Milestones Appendix
Companies MentionedAbbVie Inc Apexigen Inc Arog Pharmaceuticals Inc AstraZeneca Plc Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Burzynski Research Institute Inc Celgene Corp DNAtrix Inc Insys Therapeutics Inc Loxo Oncology Inc Medicenna Therapeutics Corp Midatech Pharma Plc Moleculin Biotech Inc NewLink Genetics Corp Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc PTC Therapeutics Inc Sanofi Sumitomo Dainippon Pharma Co Ltd ZIOPHARM Oncology Inc
For more information about this report visit https://www.researchandmarkets.com/research/jjfx4j/pontine_glioma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005508/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/06/2018 04:50 AM/DISC: 06/06/2018 04:50 AM